

Soonmyung Paik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2245284/publications.pdf>

Version: 2024-02-01

94
papers

37,369
citations

43973

48
h-index

40881

93
g-index

96
all docs

96
docs citations

96
times ranked

29469
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 2817-2826. | 13.9 | 5,646 |
| 2 | Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 1673-1684. | 13.9 | 4,956 |
| 3 | Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2013, 31, 3997-4013. | 0.8 | 3,276 |
| 4 | Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. <i>Lancet</i> , The, 2014, 384, 164-172. | 6.3 | 3,224 |
| 5 | American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2784-2795. | 0.8 | 2,667 |
| 6 | Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 3726-3734. | 0.8 | 2,369 |
| 7 | Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 111-121. | 13.9 | 1,558 |
| 8 | Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. <i>Journal of Clinical Oncology</i> , 2008, 26, 778-785. | 0.8 | 1,524 |
| 9 | Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 2005-2014. | 13.9 | 1,146 |
| 10 | Nanomaterials for Theranostics: Recent Advances and Future Challenges. <i>Chemical Reviews</i> , 2015, 115, 327-394. | 23.0 | 1,063 |
| 11 | Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1446-1452. | 3.0 | 899 |
| 12 | Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. <i>Journal of Clinical Oncology</i> , 2006, 24, 2019-2027. | 0.8 | 850 |
| 13 | erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 1998, 90, 1361-1370. | 3.0 | 620 |
| 14 | Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor-Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20. <i>Journal of Clinical Oncology</i> , 2010, 28, 1677-1683. | 0.8 | 538 |
| 15 | Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 721-728. | 0.8 | 536 |
| 16 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251. | 2.4 | 469 |
| 17 | Real-World Performance of HER2 Testing--National Surgical Adjuvant Breast and Bowel Project Experience. <i>Journal of the National Cancer Institute</i> , 2002, 94, 852-854. | 3.0 | 463 |
| 18 | HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer. <i>New England Journal of Medicine</i> , 2008, 358, 1409-1411. | 13.9 | 416 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 211-222. | 13.9 | 388 |
| 20 | Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2395-2405. | 13.9 | 349 |
| 21 | Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. <i>Lancet, The</i> , 2019, 394, 2155-2164. | 6.3 | 319 |
| 22 | Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value. <i>Clinical Cancer Research</i> , 2012, 18, 6531-6541. | 3.2 | 272 |
| 23 | HER2 and Choice of Adjuvant Chemotherapy for Invasive Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1991-1998. | 3.0 | 258 |
| 24 | NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+. <i>Journal of Clinical Oncology</i> , 2020, 38, 444-453. | 0.8 | 234 |
| 25 | Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. <i>Annals of Oncology</i> , 2015, 26, 1280-1291. | 0.6 | 177 |
| 26 | Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 133-142. | 1.1 | 176 |
| 27 | Development and Clinical Utility of a 21-Gene Recurrence Score Prognostic Assay in Patients with Early Breast Cancer Treated with Tamoxifen. <i>Oncologist</i> , 2007, 12, 631-635. | 1.9 | 167 |
| 28 | Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin. <i>Journal of Clinical Oncology</i> , 2013, 31, 4512-4519. | 0.8 | 155 |
| 29 | Gene-expression-based prognostic assays for breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 340-347. | 12.5 | 146 |
| 30 | Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes. <i>JAMA Oncology</i> , 2016, 2, 1162. | 3.4 | 140 |
| 31 | Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. <i>Lancet Oncology, The</i> , 2015, 16, 1037-1048. | 5.1 | 138 |
| 32 | Estrogen Receptor (<i>ESR1</i>) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4160-4167. | 0.8 | 120 |
| 33 | 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw259. | 3.0 | 116 |
| 34 | A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. <i>BMC Cancer</i> , 2010, 10, 101. | 1.1 | 115 |
| 35 | Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG) Tj ETQq1 1 0.784314 rgBT /Overlock <i>The</i> , 2019, 20, 88-99. | 5.1 | 108 |
| 36 | Intrinsic Subtypes, <i>PIK3CA</i> Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1340-1347. | 0.8 | 105 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy. <i>JAMA Oncology</i> , 2020, 6, 367. | 3.4 | 100 |
| 38 | Association of Polymorphisms in <i>FCGR2A</i> and <i>FCGR3A</i> With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 335. | 3.4 | 96 |
| 39 | Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1782-1788. | 3.0 | 94 |
| 40 | Technology Insight: application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 246-254. | 4.3 | 85 |
| 41 | Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT. <i>Gastroenterology</i> , 2018, 155, 799-814.e13. | 0.6 | 83 |
| 42 | Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (<i>ESR1</i>) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14. <i>Journal of Clinical Oncology</i> , 2016, 34, 2350-2358. | 0.8 | 71 |
| 43 | 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 37. | 2.3 | 65 |
| 44 | Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention. <i>Cancer Discovery</i> , 2013, 3, 812-825. | 7.7 | 61 |
| 45 | Targeting mutant <i>KRAS</i> with CRISPR-Cas9 controls tumor growth. <i>Genome Research</i> , 2018, 28, 374-382. | 2.4 | 59 |
| 46 | Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08. <i>Journal of the National Cancer Institute</i> , 2013, 105, 989-992. | 3.0 | 56 |
| 47 | Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck. <i>Clinical Cancer Research</i> , 2015, 21, 544-552. | 3.2 | 56 |
| 48 | Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3507-3507. | 0.8 | 53 |
| 49 | Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. <i>Journal of Clinical Oncology</i> , 2019, 37, 3425-3435. | 0.8 | 51 |
| 50 | Is gene array testing to be considered routine now?. <i>Breast</i> , 2011, 20, S87-S91. | 0.9 | 49 |
| 51 | Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 9050. | 1.6 | 43 |
| 52 | Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 867-871. | 3.0 | 41 |
| 53 | Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. <i>Oncotarget</i> , 2016, 7, 24172-24178. | 0.8 | 41 |
| 54 | Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype. <i>Oncotarget</i> , 2017, 8, 39367-39381. | 0.8 | 38 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 69-77. | 1.1 | 36 |
| 56 | NSABP B-51/RTOG 1304: Randomized phase III clinical trial evaluating the role of postmastectomy chest wall and regional nodal XRT (CWRNRT) and post-lumpectomy RNRT in patients (pts) with documented positive axillary (Ax) nodes before neoadjuvant chemotherapy (NC) who convert to pathologically negative Ax nodes after NC. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS1141-TPS1141. | 0.8 | 31 |
| 57 | NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 133. | 2.2 | 30 |
| 58 | Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2021, 143, 113-126. | 1.3 | 30 |
| 59 | Expression analysis of mRNA in formalin-fixed, paraffin-embedded archival tissues by mRNA in situ hybridization. <i>Methods</i> , 2006, 38, 253-262. | 1.9 | 26 |
| 60 | Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. <i>Lung Cancer</i> , 2018, 124, 168-178. | 0.9 | 23 |
| 61 | A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 517-523. | 1.1 | 22 |
| 62 | PI3K/AKT/ β -Catenin Signaling Regulates Vestigial-Like 1 Which Predicts Poor Prognosis and Enhances Malignant Phenotype in Gastric Cancer. <i>Cancers</i> , 2019, 11, 1923. | 1.7 | 22 |
| 63 | Destabilization of β -catenin and RAS by targeting the Wnt/ β -catenin pathway as a potential treatment for triple-negative breast cancer. <i>Experimental and Molecular Medicine</i> , 2020, 52, 832-842. | 3.2 | 21 |
| 64 | Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in <i>RET</i> -Rearranged Lung Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2238-2248. | 1.9 | 19 |
| 65 | Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy. <i>International Journal of Cancer</i> , 2020, 146, 1851-1861. | 2.3 | 19 |
| 66 | Clinical trial methods to discover and validate predictive markers for treatment response in cancer. <i>Biotechnology Annual Review</i> , 2003, 9, 259-267. | 2.1 | 18 |
| 67 | Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology). <i>British Journal of Cancer</i> , 2018, 118, 629-633. | 2.9 | 18 |
| 68 | Bcl-2-dependent synthetic lethal interaction of the IDF-11774 with the V0 subunit C of vacuolar ATPase (ATP6VOC) in colorectal cancer. <i>British Journal of Cancer</i> , 2018, 119, 1347-1357. | 2.9 | 18 |
| 69 | Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck. <i>British Journal of Cancer</i> , 2020, 123, 1720-1729. | 2.9 | 18 |
| 70 | Gene Expression-Based Prognostic and Predictive Markers for Breast Cancer: A Primer for Practicing Pathologists. <i>Archives of Pathology and Laboratory Medicine</i> , 2009, 133, 855-859. | 1.2 | 18 |
| 71 | Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine. <i>Yonsei Medical Journal</i> , 2015, 56, 1186. | 0.9 | 14 |
| 72 | Establishment and characterization of patient-derived xenografts as preclinical models for head and neck cancer. <i>BMC Cancer</i> , 2020, 20, 316. | 1.1 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2015, 6, 44971-44984. | 0.8 | 13 |
| 74 | Association between <i>Fusobacterium nucleatum</i> and patient prognosis in metastatic colon cancer. <i>Scientific Reports</i> , 2021, 11, 20263. | 1.6 | 11 |
| 75 | Systematic evaluation of scoring methods for Ki67 as a surrogate for 21-gene recurrence score. <i>Npj Breast Cancer</i> , 2021, 7, 13. | 2.3 | 10 |
| 76 | A Therapeutic Strategy for Chemotherapy-Resistant Gastric Cancer via Destabilization of Both β -Catenin and RAS. <i>Cancers</i> , 2019, 11, 496. | 1.7 | 9 |
| 77 | An Improved, Assay Platform Agnostic, Absolute Single Sample Breast Cancer Subtype Classifier. <i>Cancers</i> , 2020, 12, 3506. | 1.7 | 9 |
| 78 | Association of colon cancer (CC) molecular signatures with prognosis and oxaliplatin prediction-benefit in the MOSAIC Trial (Multicenter International Study of Oxaliplatin/5FU-LV in the T) <i>ETQq000rg88/Overlock10Tf5</i> | 0.8 | 8 |
| 79 | EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E Mutant NSCLC Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1627-1636. | 1.9 | 8 |
| 80 | The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. <i>Annals of Surgical Oncology</i> , 2017, 24, 1853-1860. | 0.7 | 8 |
| 81 | Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations. <i>PLoS ONE</i> , 2018, 13, e0200836. | 1.1 | 8 |
| 82 | Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. <i>Oncotarget</i> , 2017, 8, 38389-38398. | 0.8 | 8 |
| 83 | Immune Signature to Predict Trastuzumab Benefit: Potential and Pitfalls. <i>Journal of Clinical Oncology</i> , 2015, 33, 3671-3672. | 0.8 | 5 |
| 84 | Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma. <i>IScience</i> , 2020, 23, 101386. | 1.9 | 5 |
| 85 | BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy. <i>Cancer Research and Treatment</i> , 2019, 51, 1527-1539. | 1.3 | 5 |
| 86 | Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 147-152. | 0.7 | 4 |
| 87 | Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 255-262. | 1.1 | 3 |
| 88 | AIRVF: a filtering toolbox for precise variant calling in Ion Torrent sequencing. <i>Bioinformatics</i> , 2018, 34, 1232-1234. | 1.8 | 3 |
| 89 | Genomic landscape of extraordinary responses in metastatic breast cancer. <i>Communications Biology</i> , 2021, 4, 449. | 2.0 | 3 |
| 90 | Response: Re: Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1559-1560. | 3.0 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 91 | Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831. JNCI Cancer Spectrum, 2020, 4, pkaa058. | 1.4 | 2 |
| 92 | Prognostic Tests for Estrogen Receptor-Positive Breast Cancer. JAMA Oncology, 2016, 2, 180. | 3.4 | 1 |
| 93 | Copy number aberration burden on circulating tumor DNA predicts recurrence risk after neoadjuvant chemotherapy in patients with triple-negative breast cancer: Post-hoc analysis of phase III PEARLY trial.. Journal of Clinical Oncology, 2022, 40, 603-603. | 0.8 | 1 |
| 94 | Assays for Gene Amplification. , 2006, , 65-77. | | 0 |